Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Terns Pharmaceuticals, Inc. (TERN) EBITDA (2020 - 2023)

Terns Pharmaceuticals (TERN) has disclosed EBITDA for 4 consecutive years, with -$24.1 million as the latest value for Q4 2023.

  • For the quarter ending Q4 2023, EBITDA fell 42.96% year-over-year to -$24.1 million, compared with a TTM value of -$93.3 million through Dec 2023, down 49.14%, and an annual FY2024 reading of -$89.1 million, up 13.11% over the prior year.
  • EBITDA was -$24.1 million for Q4 2023 at Terns Pharmaceuticals, up from -$29.8 million in the prior quarter.
  • Across five years, EBITDA topped out at -$8.8 million in Q4 2020 and bottomed at -$29.8 million in Q3 2023.
  • Average EBITDA over 4 years is -$15.3 million, with a median of -$14.0 million recorded in 2021.
  • The sharpest move saw EBITDA decreased 5.28% in 2021, then plummeted 72.5% in 2023.
  • Year by year, EBITDA stood at -$8.8 million in 2020, then plummeted by 58.28% to -$13.9 million in 2021, then dropped by 21.26% to -$16.8 million in 2022, then crashed by 42.96% to -$24.1 million in 2023.
  • Business Quant data shows EBITDA for TERN at -$24.1 million in Q4 2023, -$29.8 million in Q3 2023, and -$18.3 million in Q2 2023.